PUBLISHER: DelveInsight | PRODUCT CODE: 1128281
PUBLISHER: DelveInsight | PRODUCT CODE: 1128281
"BESREMi Drug Insight and Market Forecast - 2032" report provides comprehensive insights about BESREMi for Polycythemia Vera in the 7MM. A detailed picture of the BESREMi for Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the BESREMi for Polycythemia Vera. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the BESREMi market forecast, analysis for Polycythemia Vera in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Polycythemia Vera.
BESREMi (ropeginterferon alfa-2B/AOP2014/P1101) is mono-pegylated proline interferon approved as first-line monotherapy in adults for the treatment of Polycythemia Vera (PV) without symptomatic splenomegaly. It is one of the first of its kind to be approved for the condition. It is a long-acting, mono-pegylated proline interferon developed using PharmaEssentia's novel pegylation technology platform. The drug has exhibited improved pharmacokinetic properties in clinical studies, including increased tolerability and convenience. BESREMi is designed to be self-administered subcutaneously with a pen once every 2 weeks or monthly during long-term maintenance. This treatment schedule is expected to improve overall safety, tolerability, and adherence compared to conventional pegylated interferons.
BESREMi has been shown to induce complete hematologic and high clinical response rates with good tolerability, as well as high molecular response rates and disease-modifying capabilities, which may result in a delay of disease progression. It also showed high molecular response rates, associated with the ability to reduce the allelic burden of both mutant JAK2 and, importantly, also non JAK2 mutations, which are believed to play a role in disease progression.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
BESREMi Analytical Perspective by DelveInsight
This report provides a detailed market assessment of BESREMi in Polycythemia Vera in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.
The report provides the clinical trials information of BESREMi for Polycythemia Vera covering trial interventions, trial conditions, trial status, start and completion dates.
Key Questions